We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Ovarian Cancer - Pipeline Review, H1 2018

Published: June 2018
Pages: 2412
Code: 0BCBBA95A028CEDFE22CF7084C54473D
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,500.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide , provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.
Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide , provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 15, 152, 147, 11, 209, 28 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 47 and 8 molecules, respectively.
Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • - The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Companies Mentioned

3-V Biosciences Inc
4SC AG
AB Science SA
AbbVie Inc
Adaptimmune Therapeutics Plc
Adgero Biopharmaceuticals Holdings Inc
Advenchen Laboratories LLC
Aeterna Zentaris Inc
Agenus Inc
Alethia Biotherapeutics Inc
AlfaSigma SpA
Alkermes Plc
Allist Shanghai Pharmaceutical Technology Co Ltd
Alpha Cancer Technologies Inc
Alteogen Inc
Altor BioScience Corp
Ambrx Inc
Amgen Inc
AnGes Inc
ANP Technologies Inc
AntiCancer Inc
Antigen Express Inc
Antoxis Ltd
Aphios Corp
Aposense Ltd
Aprea AB
Arcus Biosciences Inc
arGEN-X BV
ARMO Biosciences Inc
Armour Therapeutics Inc
ArQule Inc
Array BioPharma Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
AVEO Pharmaceuticals Inc
Avipep Pty Ltd
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
BioCancell Ltd
BioEclipse Therapeutics Inc
BioMoti Ltd
Bionomics Ltd
BioNTech AG
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Caladrius Biosciences Inc
Calithera Biosciences Inc
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celon Pharma SA
Celprogen Inc
Celsion Corp
Celyad SA
CerRx Inc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Clovis Oncology Inc
CohBar Inc
Coherus BioSciences Inc
Commence Bio Inc
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
Curis Inc
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
CZ BioMed Corp
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Eli Lilly and Co
EntreChem SL
Epigen Biosciences Inc
EpiThany Inc
Epizyme Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Five Prime Therapeutics Inc
Formation Biologics Inc
Forty Seven Inc
Fujifilm Holdings Corporation
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Genisphere LLC
Genmab A/S
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Glycotope GmbH
GP Pharm SA
Gradalis Inc
GW Pharmaceuticals Plc
Halozyme Therapeutics Inc
Harbin Gloria Pharmaceuticals Co Ltd
Hemispherx Biopharma Inc
Horizon Pharma Plc
Ideaya Biosciences Inc
IGF Oncology LLC
Ignyta Inc
Ildong Pharmaceutical Co Ltd
IMMD Inc
Immix BioPharma Inc
Immune Design Corp
Immune Pharmaceuticals Inc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Immutep Ltd
IMPACT Therapeutics Inc
Imugene Ltd
IMV Inc
Incyte Corp
Innate Pharma SA
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Inventiva
Iovance Biotherapeutics Inc
ITUS Corp
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kiromic Inc
Kringle Pharma Inc
Kyowa Hakko Kirin Co Ltd
Laboratoire HRA Pharma SAS
Lantern Pharma Inc
LATITUDE Pharmaceuticals Inc
Leap Therapeutics Inc
LegoChem Biosciences Inc
Lidds AB
Lixte Biotechnology Holdings Inc
Loxo Oncology Inc
Lycera Corp
Lymphocyte Activation Technologies SA
MabVax Therapeutics Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc
Mateon Therapeutics Inc
MaxCyte Inc
MaxiVAX SA
Mebiopharm Co Ltd
MediaPharma SRL
MediciNova Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
Millennium Pharmaceuticals Inc
Minerva Biotechnologies Corp
Mirati Therapeutics Inc
Molecular Templates Inc
Moleculin Biotech Inc
Monopar Therapeutics Inc
Morphotek Inc
Mycenax Biotech Inc
NanoVector Inc
NantKwest Inc
Natco Pharma Ltd
NBE-Therapeutics AG
Nektar Therapeutics
Neovacs SA
Nerviano Medical Sciences Srl
Neurimmune Holding AG
NewLink Genetics Corp
Northern Biologics Inc
Northwest Biotherapeutics Inc
Novartis AG
NovaTarg Therapeutics Inc
Noviga Research AB
Noxopharm Ltd
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Omeros Corp
Omnitura Therapeutics Inc
OncBioMune Pharmaceuticals Inc
Oncobiologics Inc
Oncodesign SA
Oncolix Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
OncoResponse Inc
OncoTartis Inc
OncoTherapy Science Inc
Oncovir Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
ORCA Therapeutics BV
Oric Pharmaceuticals Inc
Oxford BioMedica Plc
Pangaea Biotech SL
Patrys Ltd
PDS Biotechnology Corp
PEP-Therapy SAS
Pfizer Inc
Pharma Mar SA
PharmAust Ltd
Pharmicell Co Ltd
Plexxikon Inc
Precision Biologics Inc
Propanc Biopharma Inc
Protheragen Inc
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Recepta Biopharma SA
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
Rigel Pharmaceuticals Inc
RS Research
Rubicon Biotechnology Inc
RXi Pharmaceuticals Corp
Samumed LLC
Sanofi
Sanofi Pasteur SA
SATT North SAS
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Sequoia Sciences Inc
Siamab Therapeutics Inc
Sichuan Kelun Pharmaceutical Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sitka Biopharma Inc
Soricimed Biopharma Inc
Sotio AS
Sphaera Pharma Pte Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Supratek Pharma Inc
Susavion Biosciences Inc
Sutro Biopharma Inc
Symic Biomedical Inc
Syndax Pharmaceuticals Inc
Synergys Biotherapeutics Inc
Synthon Holdings BV
Syros Pharmaceuticals Inc
Tactiva Therapeutics LLC
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Takis Srl
TapImmune Inc
Targovax ASA
Tarveda Therapeutics Inc
TC BioPharm Ltd
TCR2 Therapeutics Inc
Tesaro Inc
TheraTarget Inc
Tocagen Inc
Tolero Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
Transgene SA
Trovagene Inc
Tyrogenex Inc
ValiRx Plc
Vascular Biogenics Ltd
Vectorite Biomedical Inc
Verastem Inc
VG Life Sciences Inc
ViraTherapeutics GmbH
Vyriad Inc
XuanZhu Pharma Co Ltd
Yooyoung Pharm Co Ltd
Zymeworks Inc

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • Table of Contents 2
  • Introduction 13
  • Ovarian Cancer - Overview 14
  • Ovarian Cancer - Therapeutics Development 15
  • Ovarian Cancer - Therapeutics Assessment 79
  • Ovarian Cancer - Companies Involved in Therapeutics Development 111
  • Ovarian Cancer - Drug Profiles 245
  • Ovarian Cancer - Dormant Projects 2303
  • Ovarian Cancer - Discontinued Products 2330
  • Ovarian Cancer - Product Development Milestones 2335
  • Appendix 2348
  • List of Tables
  • Number of Products under Development for Ovarian Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
  • Ovarian Cancer - Pipeline by 4SC AG, H1 2018
  • Ovarian Cancer - Pipeline by AB Science SA, H1 2018
  • Ovarian Cancer - Pipeline by AbbVie Inc, H1 2018
  • Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018
  • Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H1 2018
  • Ovarian Cancer - Pipeline by Agenus Inc, H1 2018
  • Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2018
  • Ovarian Cancer - Pipeline by AlfaSigma SpA, H1 2018
  • Ovarian Cancer - Pipeline by Alkermes Plc, H1 2018
  • Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H1 2018
  • Ovarian Cancer - Pipeline by Alteogen Inc, H1 2018
  • Ovarian Cancer - Pipeline by Altor BioScience Corp, H1 2018
  • Ovarian Cancer - Pipeline by Ambrx Inc, H1 2018
  • Ovarian Cancer - Pipeline by Amgen Inc, H1 2018
  • Ovarian Cancer - Pipeline by AnGes Inc, H1 2018
  • Ovarian Cancer - Pipeline by ANP Technologies Inc, H1 2018
  • Ovarian Cancer - Pipeline by AntiCancer Inc, H1 2018
  • Ovarian Cancer - Pipeline by Antigen Express Inc, H1 2018
  • Ovarian Cancer - Pipeline by Antoxis Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Aphios Corp, H1 2018
  • Ovarian Cancer - Pipeline by Aposense Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Aprea AB, H1 2018
  • Ovarian Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
  • Ovarian Cancer - Pipeline by arGEN-X BV, H1 2018
  • Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
  • Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H1 2018
  • Ovarian Cancer - Pipeline by ArQule Inc, H1 2018
  • Ovarian Cancer - Pipeline by Array BioPharma Inc, H1 2018
  • Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
  • Ovarian Cancer - Pipeline by Astellas Pharma Inc, H1 2018
  • Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
  • Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018
  • Ovarian Cancer - Pipeline by Athenex Inc, H1 2018
  • Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
  • Ovarian Cancer - Pipeline by Bayer AG, H1 2018
  • Ovarian Cancer - Pipeline by BeiGene Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H1 2018
  • Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2018
  • Ovarian Cancer - Pipeline by BioEclipse Therapeutics Inc, H1 2018
  • Ovarian Cancer - Pipeline by BioMoti Ltd, H1 2018
  • Ovarian Cancer - Pipeline by Bionomics Ltd, H1 2018
  • Ovarian Cancer - Pipeline by BioNTech AG, H1 2018
  • Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
  • Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • List of Figures
  • Number of Products under Development for Ovarian Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

Keywords
;